• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Hepatitis B Virus Reactivation under Ibrutinib Treatment in a Patient with Chronic Lymphocytic Leukemia.

作者信息

İskender Gülşen, İskender Dicle, Ertek Mustafa

机构信息

Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Clinic of Infectious Diseases and Clinical Microbiology, Ankara, Turkey

Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Clinic of Hematology and Blood and Marrow Transplantation, Ankara, Turkey

出版信息

Turk J Haematol. 2020 Aug 28;37(3):208-209. doi: 10.4274/tjh.galenos.2020.2019.0180. Epub 2020 Apr 6.

DOI:10.4274/tjh.galenos.2020.2019.0180
PMID:32248674
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7463206/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dab9/7463206/07851635d706/TJH-37-208-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dab9/7463206/07851635d706/TJH-37-208-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dab9/7463206/07851635d706/TJH-37-208-g1.jpg

相似文献

1
Hepatitis B Virus Reactivation under Ibrutinib Treatment in a Patient with Chronic Lymphocytic Leukemia.依鲁替尼治疗慢性淋巴细胞白血病患者过程中出现的乙型肝炎病毒再激活
Turk J Haematol. 2020 Aug 28;37(3):208-209. doi: 10.4274/tjh.galenos.2020.2019.0180. Epub 2020 Apr 6.
2
Prognostic models in chronic lymphocytic leukemia patients receiving ibrutinib therapy: Results of a comparative performance analysis.接受依鲁替尼治疗的慢性淋巴细胞白血病患者的预后模型：比较性能分析结果
Eur J Haematol. 2021 Mar;106(3):425-427. doi: 10.1111/ejh.13548. Epub 2020 Nov 29.
3
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study.接受依鲁替尼治疗的真实世界复发/难治性慢性淋巴细胞白血病患者的生存风险评分。一项校园慢性淋巴细胞白血病研究。
Leukemia. 2021 Jan;35(1):235-238. doi: 10.1038/s41375-020-0833-x. Epub 2020 Apr 14.
4
Ibrutinib as initial therapy in chronic lymphocytic leukemia: A systematic review and meta-analysis.伊布替尼作为慢性淋巴细胞白血病的初始治疗：一项系统评价和荟萃分析。
Eur J Haematol. 2020 May;104(5):512-515. doi: 10.1111/ejh.13387. Epub 2020 Feb 22.
5
Ibrutinib-Induced Cardiac Tamponade in Chronic Lymphocytic Leukemia.依鲁替尼诱发慢性淋巴细胞白血病患者的心包填塞
Turk J Haematol. 2021 Feb 25;38(1):83-85. doi: 10.4274/tjh.galenos.2020.2020.0446. Epub 2020 Nov 9.
6
Ibrutinib-Induced Skin Rash.依鲁替尼引起的皮疹
Turk J Haematol. 2021 Feb 25;38(1):81-83. doi: 10.4274/tjh.galenos.2020.2020.0120. Epub 2020 Oct 15.
7
Ibrutinib in Advanced Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Lower Risk of Hepatitis B Virus Reactivation.伊布替尼治疗晚期慢性淋巴细胞白血病/小淋巴细胞淋巴瘤：乙型肝炎病毒再激活风险较低
Acta Haematol. 2022;145(1):54-62. doi: 10.1159/000518398. Epub 2021 Sep 20.
8
Early morphea during treatment with ibrutinib in a patient with chronic lymphocytic leukemia.一名慢性淋巴细胞白血病患者在接受依鲁替尼治疗期间出现早期硬斑病。
Ann Hematol. 2021 Jan;100(1):293-294. doi: 10.1007/s00277-020-04009-2. Epub 2020 Mar 27.
9
Real-world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib.205 例慢性淋巴细胞白血病患者接受伊布替尼治疗的真实世界结果。
Eur J Haematol. 2020 Nov;105(5):646-654. doi: 10.1111/ejh.13499. Epub 2020 Aug 26.
10
Emerging bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia: one step ahead ibrutinib.新兴布鲁顿酪氨酸激酶抑制剂治疗慢性淋巴细胞白血病：伊布替尼更进一步。
Expert Opin Emerg Drugs. 2020 Mar;25(1):25-35. doi: 10.1080/14728214.2020.1724282. Epub 2020 Feb 6.

引用本文的文献

1
Hepatitis B virus reactivation in patients with hematologic malignancies treated with Bruton tyrosine kinase inhibitors.接受布鲁顿酪氨酸激酶抑制剂治疗的血液系统恶性肿瘤患者中的乙型肝炎病毒再激活
Blood Res. 2025 Aug 15;60(1):45. doi: 10.1007/s44313-025-00093-3.
2
Hepatitis B virus reactivation in seronegative occult hepatitis B patient receiving ibrutinib therapy.在接受伊布替尼治疗的乙型肝炎病毒表面抗原阴性隐匿性乙型肝炎患者中乙型肝炎病毒再激活。
Virol J. 2023 Aug 1;20(1):168. doi: 10.1186/s12985-023-02140-w.
3
How We Manage Patients with Indolent B-Cell Malignancies on Bruton's Tyrosine Kinase Inhibitors: Practical Considerations for Nurses and Pharmacists.

本文引用的文献

1
Immunosuppressive therapy and the risk of hepatitis B reactivation: Consensus report.免疫抑制治疗与乙型肝炎再激活风险：共识报告
Turk J Gastroenterol. 2018 May;29(3):259-269. doi: 10.5152/tjg.2018.18263.
2
Risk of hepatitis B virus reactivation in patients treated with ibrutinib.接受依鲁替尼治疗的患者中乙型肝炎病毒再激活的风险。
Blood. 2018 Apr 26;131(17):1987-1989. doi: 10.1182/blood-2018-01-826495. Epub 2018 Feb 28.
3
Severe hepatitis B virus reactivation related to ibrutinib monotherapy.与伊布替尼单药治疗相关的严重乙型肝炎病毒再激活
我们如何管理接受布鲁顿酪氨酸激酶抑制剂治疗的惰性 B 细胞恶性肿瘤患者：护士和药师的实用注意事项。
Curr Oncol. 2023 Apr 18;30(4):4222-4245. doi: 10.3390/curroncol30040322.
4
Hepatitis B Virus Reactivation in a Chronic Lymphocytic Leukemia Patient Treated with Ibrutinib.接受依鲁替尼治疗的慢性淋巴细胞白血病患者发生乙肝病毒再激活
Cancer Res Treat. 2023 Apr;55(2):704-705. doi: 10.4143/crt.2022.1524.
5
Risk of hepatitis B virus reactivation in chronic lymphocytic leukemia patients receiving ibrutinib with or without antiviral prophylaxis. A retrospective multicentric GIMEMA study.接受依鲁替尼治疗的慢性淋巴细胞白血病患者无论有无抗病毒预防措施时乙肝病毒再激活的风险。一项回顾性多中心GIMEMA研究。
Haematologica. 2022 Jun 1;107(6):1470-1473. doi: 10.3324/haematol.2021.280325.
Ann Hematol. 2017 Apr;96(4):689-690. doi: 10.1007/s00277-016-2917-2. Epub 2017 Jan 5.
4
Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.伊布替尼治疗伴有 17p 缺失的复发或难治性慢性淋巴细胞白血病患者（RESONATE-17）：一项 2 期、开放标签、多中心研究。
Lancet Oncol. 2016 Oct;17(10):1409-1418. doi: 10.1016/S1470-2045(16)30212-1. Epub 2016 Sep 13.
5
Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5).血液恶性肿瘤患者和造血干细胞移植患者的病毒性肝炎管理：第 5 届欧洲白血病感染会议（ECIL-5）的建议。
Lancet Infect Dis. 2016 May;16(5):606-617. doi: 10.1016/S1473-3099(16)00118-3. Epub 2016 Apr 18.
6
Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma.布鲁顿酪氨酸激酶抑制剂在慢性淋巴细胞白血病和淋巴瘤中的应用
Clin Adv Hematol Oncol. 2016 Jul;14(7):543-54.
7
Occult HBV reactivation induced by ibrutinib treatment: a case report.依鲁替尼治疗引起的隐匿性乙肝病毒再激活：一例报告
Acta Gastroenterol Belg. 2015 Dec;78(4):424-6.
8
American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.美国胃肠病学会关于免疫抑制药物治疗期间预防和治疗乙型肝炎病毒再激活的指南。
Gastroenterology. 2015 Jan;148(1):215-9; quiz e16-7. doi: 10.1053/j.gastro.2014.10.039. Epub 2014 Oct 31.